Patents by Inventor Hiroyasu Toyota

Hiroyasu Toyota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of enzalutamide
    Patent number: 11839689
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: December 12, 2023
    Assignees: Astellas Pharma Inc., Medivation Prostate Therapeutics LLC
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Formulations of Enzalutamide
    Publication number: 20230210778
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: July 6, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20230122911
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: November 11, 2022
    Publication date: April 20, 2023
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20200060976
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 27, 2020
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20190209476
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: July 24, 2018
    Publication date: July 11, 2019
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170224624
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 10, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • Tablet containing composite with cyclodextrin
    Patent number: 9675549
    Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Ambit Biosciences Corporation
    Inventors: Shinsuke Oba, Hiroyasu Toyota, Satomi Ikeuchi, Takumi Hara, Emiko Murayama, Kei Motonaga
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20170027910
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: February 8, 2016
    Publication date: February 2, 2017
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • ORALLY ADMINISTERED MEDICAL COMPOSITION
    Publication number: 20150306090
    Abstract: In order to provide the medical field with a single formulation comprising a modified release portion containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release portion containing solifenacin or a pharmaceutically acceptable salt thereof, (1) a single formulation having dissolution rates of both drugs similar to those of the current single drug formulations is provided, and (2) a single formulation having maximum percentages of dissolution of both drugs of 90% or more, and having a bioavailability equivalent to those of the current single drug formulations. Further, in order to provide a single formulation, (3) a single formulation having good productivity whereby failures in tabletting are reduced, and having good storage stability whereby the coloration of the immediate release portion is suppressed is provided.
    Type: Application
    Filed: August 30, 2013
    Publication date: October 29, 2015
    Inventors: YUUKI TSUTSUI, HIROYASU TOYOTA, TADASHI HAKOMORI
  • TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN
    Publication number: 20150250720
    Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 10, 2015
    Inventors: Shinsuke Oba, Hiroyasu Toyota, Satomi Ikeuchi, Takumi Hara, Emiko Murayama, Kei Motonaga
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140378517
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140179749
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 11, 2013
    Publication date: June 26, 2014
    Applicants: BEND RESEARCH, ASTELLAS PHARMA INC., MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
  • FORMULATIONS OF ENZALUTAMIDE
    Publication number: 20140100256
    Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
    Type: Application
    Filed: September 11, 2013
    Publication date: April 10, 2014
    Applicants: BEND RESEARCH, ASTELLAS PHARMA INC., MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi